10
Jun
Summary of Hydrocortisone references summary
The 1994 article by Jefferies, published in Medical Hypotheses, proposes that mild adrenocortical deficiency may contribute to chronic allergies, autoimmune disorders, and chronic fatigue syndrome (CFS), and suggests that small, physiologic doses of cortisol (hydrocortisone, HC) could safely treat these conditions. This response integrates Jefferies’ findings with the previously discussed studies—Wichers et al. (1999), Jódar et al. (2003), and McConnell et al. (2002)—to evaluate the safety of low-dose hydrocortisone (15 or 20 mg/day) in adults, focusing on bone health, insulin action, quality of life (QoL), metabolic safety, and the novel context of mild adrenocortical deficiency.
“Excellent practice with highly trained clinicians who truly care about their clients’ well-being. Highly recommend to anyone seeking psychotherapy!”
Rebecca Johnson, CA, USA
Donec sit amet eros. Lorem ipsum dolor sit amet, consecvtetuer adipiscing elit. Mauris fermentum dictum magna. Sed laoreet aliquam leo. Ut tellus dolor, dapibus eget, elementum vel, cursus eleifend, elit. Aenean auctor wisi et urna. Aliquam erat volutpat. Duis ac turpis. Integer rutrum ante eu lacus.
Vestibulum libero nisl, porta vel, scelerisque eget, malesuada at, neque. Vivamus eget nibh. Etiam cursus leo vel metus. Nulla facilisi. Aenean nec eros. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Suspendisse sollicitudin velit sed leo. Ut pharetra augue nec augue. Nam elit agna,endrerit sit amet, tincidunt ac, viverra sed, nulla. Donec porta diam eu massa. Quisque diam lorem, interdum vitae, dapibus ac.
Key Findings from Jefferies (1994)
- Hypothesis and Observations:
- Mild Adrenocortical Deficiency: Jefferies suggests that mild deficiencies in cortisol production or utilization, either primary (adrenal) or secondary (pituitary/hypothalamic), may underlie chronic allergies, autoimmune disorders (e.g., rheumatoid arthritis), and CFS. These conditions improve with small, physiologic HC doses (2.5–7.5 mg four times daily, totaling 10–30 mg/day).
- Clinical Evidence: Over 25 years (since 1958), Jefferies reported benefits of physiologic HC doses in patients with ovarian dysfunction, infertility, allergies (e.g., allergic rhinitis, asthma), autoimmune disorders (e.g., rheumatoid arthritis), and CFS. Benefits included reduced fatigue, improved immunity, and symptom relief without side effects typical of pharmacologic doses.
- Dosing Schedule: A four-times-daily schedule (before meals and bedtime, e.g., 5 mg x 4 = 20 mg/day) was optimal, maintaining diurnal cortisol variation and avoiding acid indigestion. Doses were adjusted based on deficiency severity (2.5–10 mg per dose), with temporary increases (up to 20 mg x 4) during stress or infection.
- Implication: Low-dose HC (10–20 mg/day) may safely address mild adrenocortical deficiency, improving symptoms without the risks of pharmacologic doses (e.g., osteoporosis, immunosuppression).
- Safety Profile:
- Side Effects: Over 2000 patient-years of experience, no significant side effects were reported with physiologic doses (≤20 mg/day). Unlike pharmacologic doses (100–300 mg/day), these did not cause hypercortisolism, osteoporosis, or immunosuppression. Mild allergic reactions to tablet fillers (lactose, cornstarch) occurred in some patients, resolved with alternative formulations (e.g., pediatric liquid).
- Immunity: Physiologic HC doses enhanced immunity, unlike pharmacologic doses, which impair it. This aligns with literature suggesting cortisol is essential for normal immunity at physiologic levels.
- Pregnancy: Over 200 babies were born to women on physiologic HC doses during pregnancy, with no harm to mothers or infants, supporting long-term safety.
- Implication: Low-dose HC (15–20 mg/day) appears safe for long-term use, including during pregnancy, with minimal risk of adverse effects.
- Limitations:
- Lack of Controlled Studies: Jefferies’ findings are based on clinical observations, not randomized controlled trials. Double-blind studies were attempted but abandoned due to clear benefits and variable dose needs.
- Diagnostic Challenges: Mild adrenocortical deficiency is not routinely tested, and normal cortisol ranges may mask subtle deficiencies. Tests like ACTH, cosyntropin stimulation, and 24-hour UFC are recommended but not standardized for mild cases.
- Publication Bias: Reports were published in reputable journals but overlooked due to the bad reputation of glucocorticoids, limited Medline coverage pre-1960s, and lack of pharmaceutical promotion for unpatented cortisol.
Integration with Previous Studies
To assess the safety of low-dose HC (15 or 20 mg/day), Jefferies’ findings are compared with Wichers et al. (1999), Jódar et al. (2003), and McConnell et al. (2002):
- Bone Health:
- Jefferies (1994): Claims physiologic HC doses (10–20 mg/day) do not promote osteoporosis, unlike pharmacologic doses. No bone-specific data (e.g., BMD, osteocalcin) were provided, but long-term use (up to 40 years) showed no bone-related side effects.
- Wichers et al. (1999): Found 15 and 20 mg/day HC had minimal impact on osteocalcin (2.3 ± 0.49 μg/l at 15 mg, 2.1 ± 0.42 μg/l at 20 mg, vs. 1.8 ± 0.38 μg/l at 30 mg; P<0.01 for 15 vs. 30 mg), within normal ranges (1.8–6.6 μg/l). Bone resorption markers were unaffected, suggesting lower doses reduce bone loss risk compared to 30 mg/day.
- Jódar et al. (2003): Reported normal BMD Z-scores (LS: -1.15 to +0.07) and no significant bone loss over 48–60 months at 30 mg/day HC, but 56% of patients had osteoporosis, particularly with prednisone. Osteocalcin was normal (6.11 ± 1.82 μg/l).
- Synthesis: Jefferies’ claim of no osteoporosis risk with 15–20 mg/day aligns with Wichers’ minimal osteocalcin suppression and Jódar’s stable BMD at 30 mg/day. Lower doses likely offer better bone safety, as 30 mg/day (Wichers, Jódar) increases osteoporosis risk, especially with prednisone (Jódar). Jefferies’ long-term anecdotal safety supports 15–20 mg/day as a safer option.
- Insulin Action and Glucose Metabolism:
- Jefferies (1994): Did not assess insulin action but noted cortisol’s role in gluconeogenesis to prevent hypoglycemia. No glucose-related adverse effects were reported with physiologic doses, suggesting metabolic safety.
- McConnell et al. (2002): Found 15 mg/day HC preserved insulin sensitivity (glucose infusion rate: 4.45 ± 0.54 mg/kg/min vs. 4.49 ± 0.62 mg/kg/min for physiological infusion; P=NS), indicating no impairment compared to physiological cortisol levels.
- Wichers et al. (1999): Normal UFC at 15–20 mg/day (298 ± 26 nmol/day at 15 mg, 454 ± 43 nmol/day at 20 mg, vs. 147–535 nmol/day) suggests physiological cortisol exposure, reducing risks of insulin resistance seen with higher doses (30 mg/day: 819 ± 59 nmol/day).
- Jódar et al. (2003): Normal serum calcium, phosphate, and creatinine at 30 mg/day HC indicate metabolic stability, with no glucose-related issues reported.
- Synthesis: McConnell’s direct evidence of preserved insulin sensitivity at 15 mg/day, combined with Wichers’ physiological UFC and Jefferies’ lack of glucose-related side effects, supports 15–20 mg/day HC as safe for glucose metabolism. Jódar’s metabolic stability at higher doses reinforces this, but lower doses avoid over-replacement risks (Wichers).
- Quality of Life (QoL):
- Jefferies (1994): Reported subjective improvements in fatigue, allergies, and autoimmune symptoms with 10–20 mg/day HC, suggesting enhanced QoL. Patients adhered to four-times-daily dosing due to noticeable benefits, with rapid symptom return upon dose omission.
- Wichers et al. (1999): Found equivalent QoL across 15, 20, and 30 mg/day HC, with scores similar to healthy individuals (e.g., BBS: 81.8–83.6 vs. >77.6), indicating 15–20 mg/day maintains well-being.
- McConnell et al. (2002): Did not assess QoL but noted clinical stability on 15 mg/day, implying adequate well-being.
- Jódar et al. (2003): Did not evaluate QoL but reported stable clinical status, suggesting no major impairments.
- Synthesis: Jefferies’ anecdotal QoL improvements align with Wichers’ robust evidence of maintained QoL at 15–20 mg/day. McConnell and Jódar’s clinical stability support this, suggesting low-dose HC effectively sustains well-being, potentially more so in mild adrenocortical deficiency (Jefferies).
- Metabolic and Clinical Safety:
- Jefferies (1994): Over 2000 patient-years, physiologic HC doses (10–20 mg/day) caused no hypercortisolism, hypokalemia, or other side effects, except rare filler allergies. Safe use during pregnancy and long-term (up to 40 years) was reported.
- Wichers et al. (1999): 15–20 mg/day HC maintained normal UFC, electrolytes, blood pressure, and weight, unlike 30 mg/day, which elevated UFC. No significant side effects were reported.
- McConnell et al. (2002): No adverse effects at 15 mg/day, with stable BMI (28.5 ± 1.5 kg/m²) and preserved insulin sensitivity.
- Jódar et al. (2003): Normal serum calcium, phosphate, and creatinine at 30 mg/day HC, with adequate calcium/vitamin D intake ensuring metabolic stability.
- Synthesis: All studies confirm metabolic safety of 15–20 mg/day HC, with normal clinical parameters (Wichers, McConnell, Jódar) and no side effects (Jefferies, Wichers, McConnell). Jefferies’ long-term experience and pregnancy safety add unique evidence, while Wichers’ UFC data and McConnell’s insulin sensitivity reinforce physiological dosing. Jódar’s stability at higher doses suggests lower doses are even safer.
- Mild Adrenocortical Deficiency Context:
- Jefferies (1994): Proposes mild adrenocortical deficiency as a common, underdiagnosed condition, supported by low cortisol in CFS (Poteliakoff, 1981; Demitrack, 1991) and benefits of physiologic HC in allergies, autoimmune disorders, and CFS. A four-times-daily schedule (e.g., 5 mg x 4 = 20 mg/day) is recommended, with stress dosing up to 80 mg/day.
- Wichers et al. (1999): Studied secondary hypocortisolism, finding 15–20 mg/day HC effective and safe, aligning with Jefferies’ physiologic dosing but not addressing mild deficiency explicitly.
- McConnell et al. (2002): Focused on hypopituitarism, confirming 15 mg/day HC’s safety for insulin action, consistent with Jefferies’ safe physiologic dosing.
- Jódar et al. (2003): Addressed Addison’s disease, not mild deficiency, but showed stable BMD at 30 mg/day HC, suggesting safety at higher doses, which supports lower doses for milder conditions.
- Synthesis: Jefferies’ hypothesis of mild adrenocortical deficiency expands the application of low-dose HC to a broader population, supported by Wichers’ and McConnell’s safety data in defined deficiencies. The lack of side effects across studies suggests 15–20 mg/day HC could be trialed in suspected mild deficiency, pending diagnostic confirmation (e.g., ACTH, cosyntropin tests).
- Prednisone vs. Hydrocortisone:
- Jefferies (1994): Prefers HC over synthetic glucocorticoids (e.g., prednisone) due to its natural profile and lack of side effects at physiologic doses. Synthetic derivatives have 4–30 times the potency and similar side effects to pharmacologic HC doses.
- Wichers et al. (1999): Focused on HC, finding 30 mg/day riskier for bone health.
- McConnell et al. (2002): Evaluated only HC, supporting its safety at 15 mg/day.
- Jódar et al. (2003): Noted higher osteoporosis prevalence with prednisone (7.5 mg/day) vs. HC (30 mg/day), despite equivalent potency.
- Synthesis: HC at 15–20 mg/day is preferred over prednisone, as it avoids osteoporosis risks (Jódar) and aligns with physiological needs (Jefferies, Wichers, McConnell). Jefferies’ emphasis on natural HC strengthens its safety profile.
Conclusion on Safety of Low-Dose Hydrocortisone
Safety Profile:
- Bone Health: 15–20 mg/day HC minimizes bone loss risk, with minimal osteocalcin suppression (Wichers) and no reported osteoporosis (Jefferies). Jódar’s high osteoporosis prevalence at 30 mg/day HC/prednisone supports lower doses for safety.
- Insulin Action: 15 mg/day HC preserves insulin sensitivity (McConnell), supported by normal UFC at 15–20 mg/day (Wichers) and no glucose-related issues (Jefferies, Jódar), reducing risks of insulin resistance.
- Quality of Life: 15–20 mg/day maintains QoL comparable to healthy individuals (Wichers) and improves symptoms in allergies, autoimmune disorders, and CFS (Jefferies). Clinical stability (McConnell, Jódar) suggests no QoL impairment.
- Metabolic Safety: Normal electrolytes, clinical parameters, and UFC (Wichers, McConnell, Jódar) and no side effects (Jefferies) confirm metabolic safety. Jefferies’ long-term (40 years) and pregnancy safety data are particularly robust.
- Mild Adrenocortical Deficiency: Jefferies’ hypothesis suggests 15–20 mg/day HC could benefit patients with mild deficiencies, supported by safety data from defined deficiencies (Wichers, McConnell). Diagnostic tests are needed to validate this condition.
Recommendations:
- Preferred Dosage: 15–20 mg/day HC, ideally 5 mg four times daily (Jefferies) or 2/3 morning, 1/3 afternoon (Wichers; e.g., 10 mg AM, 5 mg PM for 15 mg/day), is recommended for safety and efficacy in adrenal insufficiency, hypopituitarism, or suspected mild adrenocortical deficiency.
- Monitoring:
- Adrenal Function: ACTH, cortisol, cosyntropin stimulation, and 24-hour UFC to diagnose mild deficiency (Jefferies, Wichers).
- Bone Health: Osteocalcin and BMD to monitor osteoporosis risk (Wichers, Jódar).
- Glucose Metabolism: Glucose/insulin parameters to ensure insulin sensitivity (McConnell).
- QoL: Regular assessments to confirm well-being (Wichers, Jefferies).
- Stress Dosing: Temporary increases (up to 80 mg/day) during stress/infection, tapered back to 15–20 mg/day (Jefferies, Wichers).
- Prednisone Caution: HC is preferred over prednisone due to lower osteoporosis risk (Jódar) and natural physiology (Jefferies).
- Mild Deficiency Trials: Therapeutic trials with 15–20 mg/day HC may be considered for suspected mild adrenocortical deficiency, with pre-treatment testing (Jefferies). Controlled studies are needed to confirm efficacy.
- Limitations: Small sample sizes (Wichers: n=9, Jódar: n=25, McConnell: n=10) and Jefferies’ reliance on observations limit generalizability. Wichers’ short duration (6 weeks) and McConnell’s focus on acute effects contrast with Jefferies’ and Jódar’s long-term data, necessitating further research.
